Emerging Pipeline Therapeutics Across 6 Rare Neuromuscular Diseases: Strategic Partnering and New Product Development will Enable Better Biologics for Personalized and Targeted Treatment - ResearchAndMarkets.com
13 Dec 2022
Drug ApprovalImmunotherapyOligonucleotide
DUBLIN--(BUSINESS WIRE)--The "Emerging Therapeutics for Rare Neuromuscular Diseases: Pipeline Analysis" report has been added to ResearchAndMarkets.com's offering.
'Emerging Therapeutics for Rare Neuromuscular Diseases: Pipeline Analysis'
Biologics presents a personalized and targeted method to treat NMDs and is a promising treatment class. An overview of the global clinical trial landscape for emerging Phase 1, 2, and 3 treatments revealed that Amyotrophic LateralAmyotrophic Lateral Sclerosis (ALS), Myasthenia Gravis (MG), Duchenne Muscular Dystrophy (DMD), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Diabetic Neuropathy (DN), and Spinal Muscular Atrophy (SMA) are the key hotspots for clinical studies. These indications are likely to witness new drug developments.
This research, "Emerging Therapeutics for Rare Neuromuscular Diseases: A Pipeline Analysis" explores emerging biologics across these six NMDs.
Muscle weakness, cramps, and impaired musculoskeletal functions that occur due to rare defects in nerve and muscle cells characterize neuromuscular disorders (NMDs). The disorders are largely classified as motor neuron diseases, hereditary ataxias, peripheral nerve disorders, neuromuscular junction transmission disorders, and myopathies.
NMDs present significant clinical challenges because of disease heterogeneity and rarity of occurrence. The lack of measurable early disease markers and clinical outcomes further complicates the management of such disorders.
Key biologics emerging for these rare NMDs include stem cell therapies, other cell-based treatments, gene therapies, RNA therapeutics, immunotherapies, and other protein/peptide-based treatments. There were 3 recent US FDA approvals for NMD RNA therapies: Nusinersen for SMA and Eteplirsen for DMD in 2016, and Golodirsen for DMD in 2019.
Furthermore, Sarepta's Casimersen for DMD and argenx's efgartigimod for MG were approved as recently as 2021. Biologics have opened doors for ground-breaking disease-modifying treatments and will transform the quality of life for patients across the world.
While biologics may appear to cost more than small molecule treatments, they provide a personalized and, in some cases, the only treatment option. They can also be less expensive than lifetime treatment costs for certain rare NMDs. For example, Zolgensma's $2.1 million price tag (approximate) is still lower than the standard medical costs incurred for SMA patients in a lifetime. Furthermore, the evolving payer landscape is likely to get more standardized in the coming years to offer greater access to biologicals.
Therefore, biologics are suitably poised to transform the rare NMD landscape with personalized and targeted treatment strategies and will provide life-saving treatment options for fatal neuromuscular conditions.
Key Points Discussed
What are the key emerging biologics for NMDs with high clinical activity?
What are the key drivers or challenges for biologics development across NMDs?
How do venture funding and patent landscapes look for NMD biologics?
Who are the key industry participants developing biologics for NMDs?
What are the clinical trends emerging across each biologic category for NMDs?
Which biologic categories provide promising growth opportunities for NMD management?
Key Topics Covered:
Strategic Imperatives
Factors Creating Pressure on Growth
The Impact of the Top 3 Strategic Imperatives on Rare Neuromuscular Disease Management
Growth Opportunities Fuel the Growth Pipeline Engine
Growth Opportunity Analysis
Scope of Analysis
Segmentation
Predominant Emerging Biologic Classes Across NMDs
Growth Drivers
Growth Restraints
Growth Environment
Sharp Growth in Investor Interest for Rare NMD Treatments
Snapshot of Venture-backed Companies that Enable Biologics Progress
Biologic Patents for NMDs
Patent Landscape - Biologics for NMDs
ALS: Biologics Pipeline Analysis
Biological Therapies for ALS
ALS Oligonucleotide Therapies, 2022
ALS Protein Therapies, 2022
Highlights of Recent Biologics Studies for ALS Treatment
Exploring New Therapy Paradigms for ALS Treatment
MG: Biologics Pipeline Analysis
Upcoming Biologics for MG Treatment
Protein Therapies for MG
Clinical Trial Progress in Biologics* for MG
DMD: Biologics Pipeline Analysis
Gene Therapies in the Emerging DMD Biologics Landscape
Exon-Skipping Therapies for DMD
Microdystrophin Gene Therapies for DMD
Oligonucleotide Therapies to Lead DMD Management
SMA: Biologics Pipeline Analysis
Approved and Emerging Biologics Classes for SMA
Biologics Transforming the Clinical Landscape for SMA
SMA ManagementSMA Management Through Groundbreaking Therapies
DN & CIDP: Biologics Pipeline Analysis
Biologics for DN Treatment
Biologics for Treatment Personalization in DN
Emerging Biologics for CIDP Treatment
Immunoglobulins for CIDP Treatments
Growth Opportunity Universe
Growth Opportunity 1: RNA Therapeutics
Growth Opportunity 2: Cell and Gene Therapeutics
Growth Opportunity 3: Protein Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/sgh4df
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.